Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $399000.0.

  • vTv Therapeutics' Interest & Investment Income fell 2083.33% to $399000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 1715.69%. This contributed to the annual value of $1.6 million for FY2024, which is 23156.78% up from last year.
  • Per vTv Therapeutics' latest filing, its Interest & Investment Income stood at $399000.0 for Q3 2025, which was down 2083.33% from $275000.0 recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Interest & Investment Income registered a high of $553000.0 during Q2 2024, and its lowest value of $1000.0 during Q1 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $152000.0 (2022), whereas its average is $226333.3.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first plummeted by 9166.67% in 2021, then surged by 38750.0% in 2024.
  • Over the past 5 years, vTv Therapeutics' Interest & Investment Income (Quarter) stood at $1000.0 in 2021, then skyrocketed by 15100.0% to $152000.0 in 2022, then crashed by 42.11% to $88000.0 in 2023, then skyrocketed by 387.5% to $429000.0 in 2024, then fell by 6.99% to $399000.0 in 2025.
  • Its Interest & Investment Income stands at $399000.0 for Q3 2025, versus $275000.0 for Q2 2025 and $331000.0 for Q1 2025.